Search results
Showing 61 to 75 of 112 results for paclitaxel
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development Reference number: GID-TA11022 Expected publication date: TBC
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.
Discontinued Reference number: GID-TAG436
Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.
Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]
Discontinued Reference number: GID-TA11209
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
Discontinued Reference number: GID-TA10234
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued Reference number: GID-TA10322
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Evidence-based recommendations on pralsetinib (Gavreto) for treating RET fusion-positive advanced non-small-cell lung cancer in adults.
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults.